文献速递脑血管病

低剂量与标准剂量阿替普酶治疗急性缺血性卒中的比较:ENCHANTED随机临床试验二次分析

Low-Dose vs Standard-Dose Alteplase for Patients With Acute Ischemic Stroke: Secondary Analysis of the ENCHANTED Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2017-01-01

该研究为ENCHANTED试验的预设二次分析,纳入3297例急性缺血性卒中患者,随机接受低剂量(0.6 mg/kg)或标准剂量(0.9 mg/kg)阿替普酶静脉溶栓。低剂量组症状性颅内出血发生率普遍较低,但降低幅度在亚组中未达统计学显著性。

要点

  • 低剂量阿替普酶在老年、亚洲或重症患者中未显示优于标准剂量的临床获益。
  • 两种剂量对90天死亡或残疾的治疗效应在各亚组间无显著交互作用。
  • 低剂量组症状性颅内出血率普遍较低,但亚组分析未达统计学显著性。

核心结论

  • 在急性缺血性卒中患者的关键人口学亚组中,低剂量阿替普酶对死亡或残疾的效应未明确优于标准剂量。
  • 需进一步研究以识别可能从低剂量阿替普酶获益的急性缺血性卒中患者。

研究设计与样本

  • 研究为ENCHANTED试验的预设二次分析,该试验为国际、随机、开放标签、盲法终点临床试验。
  • 2012年3月1日至2015年8月31日纳入3310例经脑影像确诊且符合当地溶栓标准的急性缺血性卒中患者,随机接受低剂量(0.6 mg/kg)或标准剂量(0.9 mg/kg)阿替普酶。
  • 排除13例后,最终分析纳入3297例患者,其中女性1248例(37.9%),平均(SD)年龄67(13)岁。

主要发现

  • 低剂量阿替普酶组症状性颅内出血发生率普遍降低,但按年龄、种族或严重程度分层未达统计学显著性。

关键数值与推荐

  • 主要终点为90天死亡和任何残疾的复合结局,采用改良Rankin量表评分(范围2-6分,最高分表示死亡)。
  • 低剂量阿替普酶用法:0.6 mg/kg,15%弹丸式注射,85%在1小时内输注。
  • 标准剂量阿替普酶用法:0.9 mg/kg,10%弹丸式注射,90%在1小时内输注。

临床怎么用

  • 对于急性缺血性卒中患者,低剂量阿替普酶未在老年、亚洲或重症亚组中显示优于标准剂量的临床获益。
  • 低剂量阿替普酶可能降低症状性颅内出血风险,但亚组分析未达统计学显著性,临床决策需个体化。

局限性

  • 本研究为二次分析,亚组比较可能受样本量限制而把握度不足。
  • 原始试验为开放标签设计,尽管终点评估采用盲法,仍可能存在偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: A lower dose of intravenous alteplase appears to be a safer treatment option than the standard dose, reducing the risk of symptomatic intracerebral hemorrhage. There is uncertainty, however, over how this effect translates into an overall clinical benefit for patients with acute ischemic stroke (AIS). OBJECTIVE: To assess whether older, Asian, or severely affected patients with AIS who are considered at high risk of thrombolysis may benefit more from low-dose rather than standard-dose alteplase treatment. DESIGN, SETTING, AND PARTICIPANTS: This study is a prespecified secondary analysis of the Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED), an international, randomized, open-label, blinded, end-point clinical trial of low-dose vs standard-dose intravenous alteplase for patients with AIS. From March 1, 2012, to August 31, 2015, a total of 3310 patients who had a clinical diagnosis of AIS as confirmed by brain imaging and who fulfilled the local criteria for thrombolysis treatment were included in the alteplase-dose arms. Patients were randomly assigned to receive low-dose (0.6 mg/kg; 15% as bolus and 85% as infusion over 1 hour) or standard-dose (0.9 mg/kg; 10% as bolus and 90% as infusion over 1 hour) alteplase. Of the 3310 randomized patients, 13 patients were excluded for missing consent, mistaken randomization, and duplicate randomization numbers. This secondary analysis was conducted between May 1, 2016, and April 28, 2017. MAIN OUTCOMES AND MEASURES: The primary end point was a poor outcome defined by the combination of death and any disability as scored by the modified Rankin Scale (scores range from 2 to 6, with the highest score indicating death) at 90 days. RESULTS: Of the 3297 patients included in the analysis, 1248 (37.9%) were women, and the mean (SD) age was 67 (13) years. No significant differences in the treatment effects were observed between low- and standard-dose alteplase for poor outcomes (death or disability) by age, ethnicity, or severity (all P > .37 for interaction). Similarly, the treatment effects of low- vs standard-dose alteplase on function outcome (ordinal shift of the modified Rankin Scale) in Asians (odds ratio, 1.05; 95% CI, 0.90-1.22) was consistent with non-Asians (odds ratio, 0.93; 95% CI, 0.76-1.14) (P = .32 for interaction). There were generally consistent reductions in rates of symptomatic intracerebral hemorrhage with low-dose alteplase, although this reduction was not statistically significant by age, ethnicity, or severity. CONCLUSIONS AND RELEVANCE: This analysis found that the effects of low-dose alteplase were not clearly superior to the effects of standard-dose alteplase on death or disability in key demographic subgroups of patients with AIS. Further investigation is required to identify patients with AIS who may benefit from low-dose alteplase. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01422616.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Wang X, Robinson TG, Lee TH, et al. Low-Dose vs Standard-Dose Alteplase for Patients With Acute Ischemic Stroke: Secondary Analysis of the ENCHANTED Randomized Clinical Trial. JAMA Neurol. 2017. PMID: 28973174. doi:10.1001/jamaneurol.2017.2286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。